NIFTY NINE IN NINETY NINE PLUS ONE Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : NIFTY NINE IN NINETY NINE PLUS ONE

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mike McFarland who wrote (377)	2/4/1999 6:18:00 PM
From: Steve Lokness	Read Replies (1) of 613

"The PathVysion HER-2 test is one of the first examples of genomic disease management for breast cancer, where a direct genetic test enables assessment of a patient for determination of the most appropriate therapy based upon their genetic profile." MYGN isn't the only one doing these test! Steve

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next